N4 Pharma PLC (LON:N4P) insider Nigel Theobald purchased 67,343 shares of N4 Pharma stock in a transaction dated Wednesday, April 10th. The shares were bought at an average cost of GBX 44 ($0.57) per share, for a total transaction of £29,630.92 ($38,718.05).
Shares of N4P stock traded down GBX 0.05 ($0.00) during trading hours on Friday, hitting GBX 3.70 ($0.05). 171,310 shares of the company were exchanged, compared to its average volume of 1,760,000. N4 Pharma PLC has a one year low of GBX 3.07 ($0.04) and a one year high of GBX 28.43 ($0.37). The stock has a market capitalization of $3.75 million and a price-to-earnings ratio of 37.00.
ILLEGAL ACTIVITY WARNING: This news story was reported by Baseball Daily News and is the property of of Baseball Daily News. If you are reading this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright law. The legal version of this news story can be read at https://www.baseballdailydigest.com/news/2019/05/04/nigel-theobald-buys-67343-shares-of-n4-pharma-plc-n4p-stock.html.
N4 Pharma Plc, a specialist pharmaceutical company, develops and licenses novel therapeutic products pharmaceutical and biotechnology companies in the United Kingdom. It reformulates marketed generic drugs; and improves delivery of novel and existing vaccines and therapeutics. The company is developing Sildenafil for use in treating erectile dysfunction; Sartans for the treatment of hypertension; Aprepitant for use in oncology and pain relief; and Aprepitant for the treatment of premature ejaculation.
Read More: What is the balance sheet?
Receive News & Ratings for N4 Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for N4 Pharma and related companies with MarketBeat.com's FREE daily email newsletter.